FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Compumedics Limited Stock AnalysisComprehensive stock analysis for Compumedics Limited (CMP.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCMP.AX
CMP.AX
Compumedics Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CMP.AX
Home🔹Stocks🔹Compumedics Limited

Compumedics Limited

CMP.AX•ASX

Compumedics Limited

CMP.AX•ASX
Sentiment

Your view on CMP.AX

Sentiment
Your view
CMP.AX
Compumedics Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CMP.AX
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Compumedics Limited

Industry
Medical - Devices
Sector
Healthcare
CEO
David Burton
Headquarters
30-40 Flockhart Street, Abbotsford, VIC, AU
Industry
Medical - Devices
Sector
Healthcare
CEO
David Burton
Headquarters
30-40 Flockhart Street, Abbotsford, VIC, AU
Description

Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Compumedics Limited, and the rating behind it. CMP.AX last traded at AUD 0.23, 102.2× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Compumedics Limited. Starting points for Compumedics Limited: P/E 102.2, beta 0.37 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Compumedics Limited. Compumedics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Compumedics Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Compumedics Limited. Compumedics Limited has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Compumedics Limited valued side by side against its closest peers. Compumedics Limited is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Compumedics Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Compumedics Limited executives and directors. Shares of Compumedics Limited have traded between AUD 0.21 and AUD 0.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Compumedics Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Compumedics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Compumedics Limited. Coverage tracks Compumedics Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ATX.AX — Amplia Therapeutics Limited
  • BMT.AX — Beamtree Holdings Limited
  • CSX.AX — CleanSpace Holdings Limited
  • CYC.AX — Cyclopharm Limited
  • CYP.AX — Cynata Therapeutics Limited
  • DOC.AX — Doctor Care Anywhere Group PLC
  • GSS.AX — Genetic Signatures Limited
  • IPD.AX — ImpediMed Limited

More Medical - Devices companies

  • BRSF — Brain Scientific Inc.
  • BRSYF — BrainsWay Ltd.
  • BSX — Boston Scientific Corporation
  • BTCY — Biotricity, Inc.
  • BVS — Bioventus Inc.
  • BWAY — BrainsWay Ltd.
  • CALZF — PolyNovo Limited
  • CATX — Perspective Therapeutics, Inc.

News

Latest Market News